![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Preclinical Profile of the Pangenotypic HCV NS3/4A Protease Inhibitor GS-9857
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
James G. Taylor, Todd Appleby, Ona Barauskas, Xiaowu Chen, Hadas Dvory-Sobol, Ruoyu Gong, Johnny Lee, Elham Nejati, Brian E. Schultz, Yujin Wang, Chris Yang, Mei Yu, Sheila Zipfel, Katie Chan
Gilead Sciences, Inc., Foster City, California, USA
![EASL1.gif](../images/042915/042915-7/EASL1.gif)
![EASL2.gif](../images/042915/042915-7/EASL2.gif)
![EASL3.gif](../images/042915/042915-7/EASL3.gif)
![EASL4.gif](../images/042915/042915-7/EASL4.gif)
![EASL5.gif](../images/042915/042915-7/EASL5.gif)
![EASL6.gif](../images/042915/042915-7/EASL6.gif)
![EASL7.gif](../images/042915/042915-7/EASL7.gif)
![EASL8.gif](../images/042915/042915-7/EASL8.gif)
![EASL9.gif](../images/042915/042915-7/EASL9.gif)
![EASL10.gif](../images/042915/042915-7/EASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|